Peter Kuhn, PhD

University Professor, Dean's Professor of Biological Sciences and Professor of Biological Sciences, Medicine, Biomedical Engineering, Aerospace and Mechanical Engineering and Urology

Image of Peter Kuhn, PhD
Is this your profile? Click to edit

Overview

Peter Kuhn joined the USC Dana and David Dornsife College of Letters, Arts and Sciences as Dean’s Professor of Biological Sciences in July 2014. Dr. Kuhn also has appointments as Professor of Medicine, Professor of Biomedical Engineering and Professor of Aerospace & Mechanical Engineering, a founding member of the Michelson Center for Convergent Biosciences at USC and is leading CSI-Cancer at USC. He is a scientist, educator and entrepreneur with a career long commitment in personalized medicine and individualized cancer patient care. He is focused on the redesign of cancer care. The first product from technology developed by Dr. Kuhn became available for prostate cancer care in June 2016. Dr. Kuhn’s strategy is to advance our understanding of the human body to improve the human condition for those affected by cancer. His research is shedding new light at how cancer spreads through the body and evolves over time. This new science will lead to a personalized care strategy that is biologically informed and clinically actionable. He is a physicist who trained initially at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany, Albany, NY in 1993 and his Ph.D. in 1995. He then moved to Stanford University where he joined the faculties of Medicine and Accelerator Physics as tenure track Assistant Professor. From 2002 to 2014 he established the Physics Oncology program at The Scripps Research in La Jolla, CA as tenured Associate Professor before joining USC in 2014. He has published over 200 peer scientific articles and patents resulting from his research.

Publications

  • Chromosome 6p amplification detected in blood cell-free DNA in advanced intraocular retinoblastoma. Ophthalmic Genet. 2022 12; 43(6):866-870.. View in PubMed
  • Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms. Int J Mol Sci. 2022 Nov 03; 23(21).. View in PubMed
  • Defining A Liquid Biopsy Profile of Circulating Tumor Cells and Oncosomes in Metastatic Colorectal Cancer for Clinical Utility. Cancers (Basel). 2022 Oct 06; 14(19).. View in PubMed
  • Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer. NPJ Breast Cancer. 2022 Sep 27; 8(1):112.. View in PubMed
  • Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma. Blood Adv. 2022 08 23; 6(16):4675-4690.. View in PubMed
  • Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case. NPJ Precis Oncol. 2022 Jun 21; 6(1):41.. View in PubMed
  • Liquid Biopsy Landscape in Patients with Primary Upper Tract Urothelial Carcinoma. Cancers (Basel). 2022 Jun 18; 14(12).. View in PubMed
  • Potential of Aqueous Humor as a Liquid Biopsy for Uveal Melanoma. Int J Mol Sci. 2022 Jun 02; 23(11).. View in PubMed
  • Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones. Curr Oncol. 2022 04 21; 29(5):2954-2972.. View in PubMed
  • Early detection of cancer. Science. 2022 03 18; 375(6586):eaay9040.. View in PubMed